MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

FDA Approved Products

tramadol hydrochloride
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2024/01/18
NDC:70518-0258
Tramadol Hydrochloride
Manufacturer:RPK Pharmaceuticals, Inc.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2021/10/21
NDC:53002-4320
TRAMADOL HYDROCHLORIDE
Manufacturer:DIRECT RX
Route:ORAL
Strength:100 mg in 1 1
Approved: 2020/01/21
NDC:61919-895
TRAMADOL HYDROCHLORIDE
Manufacturer:NuCare Pharmaceuticals,Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2021/05/21
NDC:68071-2410
tramadol hydrochloride
Manufacturer:Northwind Pharmaceuticals, LLC
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/03/31
NDC:51655-152

Singapore Approved Products

MABRON CAPSULE 50 mg
Manufacturer:MEDOCHEMIE LTD (Factory AZ)
Form:CAPSULE
Strength:50 mg
Online:Yes
Approved: 1995/04/05
Approval:SIN08114P
ACUGESIC TABLET 50 mg
Manufacturer:DUOPHARMA (M) SDN BHD
Form:TABLET
Strength:50 mg
Online:Yes
Approved: 1997/01/13
Approval:SIN09131P
ULTRACET TABLET
Manufacturer:Janssen Korea Ltd, Janssen Cilag S.p.A.
Form:TABLET, FILM COATED
Strength:37.5 mg
Online:Yes
Approved: 2003/09/27
Approval:SIN12432P
Tramapan Film-Coated Tablet 37.5mg/325mg
Manufacturer:Athena Drug Delivery Solutions Private Limited
Form:TABLET, FILM COATED
Strength:37.50 mg
Online:Yes
Approved: 2025/05/02
Approval:SIN17227P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath